Chemomab Therapeutics Ltd. (NASDAQ: CMMB) has reported two scientific presentations, including patient and preclinical findings supporting the possible use of its lead treatment candidate, CM-101, as a proprietary therapy for systemic sclerosis treatment.
Chemomab presents a study on CCL24 blocking
The Company’s chief scientific officer Dr. Adi Mor presented, “Blocking CCL24, a novel target regulating inflammation fibrosis and endothelial damage, shows promising potential as a treatment for Systemic Sclerosis,” during the biennial International Rheumatology Conference in Israel. Also, on March 12, 2022, University of Leeds professor Francesco Del Galdo presented “CCL24 as a Marker of Worse Prognosis in diffuse cutaneous SSc: a Promising Novel Biological Target” during the 7th Systemic Sclerosis World Congress.
Dr. Mor presented research results from the preclinical model and patient samples demonstrating that CCL24, the CM-101 target, is abundantly expressed in diffuse SSc patients’ skin and serum specimens when compared to healthy persons. CCL24 levels were also found to be related to fibrotic biomarkers and the progression of the disease. In addition, CM-101 significantly lowered skin and lung fibrosis in a well-established experimental animal model of SSc, either using prevention or therapeutic designs.
Del Galdo presented a study on relations between CCL24 serum levels and systemic sclerosis
Professor Del Galdo, Susan Cheney Professor of Experimental Medicine and Head of the Leeds University Raynaud’s and Scleroderma Programme, presented translational research that used patient specimens to explore the relationship between levels of CCL24 serum and the action and advancement of systemic sclerosis. The findings of professor Del Galdo, which show elevated CCL24 serum levels in diffuse cutaneous SSc (dcSSc) patients, confirmed the importance of CCL24 as a possible therapeutic target. In a translational patient group, high CCL24 serum levels were associated with disease activity and a worse diagnosis as evidenced by elevated fibrotic action and degradation of lung function with time.
Del Galdo said, “This translational study is the first to demonstrate that high CCL24 levels in patients with diffuse cutaneous systemic sclerosis are correlated with disease activity and a worse prognosis, as reflected by high fibrotic activity and the deterioration of lung function over time.”
